Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study.

Joan Forns Elena Dudukina David Hägg Péter Szentkúti Karin Gembert Estel Plana Alicia W Gilsenan Erzsébet Horváth-Puhó Vera Ehrenstein Johan Reutfors Cristina Rebordosa

Published in: Neurology and therapy (2022)

Our findings suggest little to no increased risk of cardiovascular and cerebrovascular events in patients treated with LDX compared with patients previously treated with other ADHD medications.

Keyphrases

attention deficit hyperactivity disorder
autism spectrum disorder
end stage renal disease
newly diagnosed
working memory
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors